Pharvaris N.V. Share Price & Technical Analysis
PHVS · $29.68 (-2.82%)
Healthcare / Biotechnology
$29.68
-2.82%
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and ac…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-4% return in May, -11% avg return in past 3 year May month.
8% return in 2026, 57% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 6% | 0% | 10% | -4% | – | – | – | – | – | – | – | 8% |
| 25 | -8% | -7% | -2% | 19% | -9% | 6% | 16% | 9% | 16% | -11% | 29% | -2% | 55% |
| 24 | 7% | -23% | 0% | 6% | -21% | -1% | -7% | 5% | 2% | 35% | -11% | -9% | -16% |
| 23 | -20% | -10% | 0% | 19% | -3% | 66% | 10% | 20% | 1% | -17% | 2% | 63% | 131% |
| 22 | 8% | -1% | 6% | -6% | 6% | 30% | -1% | -57% | -13% | -32% | -58% | 433% | 315% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.13B
P/E ratio
—
52W high
$33.33
52W low
$15.46
Volume
2,91,071
Beta
-2.33
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Pharvaris N.V. share price today?
- Pharvaris N.V. (PHVS) last traded around $29.68 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PHVS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PHVS. Download the app for real-time alerts.
- How can I analyze Pharvaris N.V. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.